ThermoGenesis Holdings Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Chris Xu
Chief executive officer
US$520.0k
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 7.5yrs |
| CEO ownership | n/a |
| Management average tenure | 7.2yrs |
| Board average tenure | 7.3yrs |
Recent management updates
Recent updates
It's Down 52% But ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Could Be Riskier Than It Looks
Apr 17
ThermoGenesis reports Q2 results
Aug 11Is ThermoGenesis Holdings (NASDAQ:THMO) Using Too Much Debt?
Oct 20Is ThermoGenesis Holdings (NASDAQ:THMO) A Risky Investment?
May 31When Will ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Become Profitable?
Apr 06Here's Why ThermoGenesis Holdings (NASDAQ:THMO) Can Afford Some Debt
Feb 10Does ThermoGenesis Holdings' (NASDAQ:THMO) CEO Salary Compare Well With Industry Peers?
Dec 15
ThermoGenesis EPS misses by $0.27, misses on revenue
Nov 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$520k | US$520k | -US$18m |
| Sep 30 2023 | n/a | n/a | -US$14m |
| Jun 30 2023 | n/a | n/a | -US$14m |
| Mar 31 2023 | n/a | n/a | -US$14m |
| Dec 31 2022 | US$699k | US$519k | -US$11m |
| Sep 30 2022 | n/a | n/a | -US$10m |
| Jun 30 2022 | n/a | n/a | -US$9m |
| Mar 31 2022 | n/a | n/a | -US$11m |
| Dec 31 2021 | US$748k | US$500k | -US$11m |
| Sep 30 2021 | n/a | n/a | -US$12m |
| Jun 30 2021 | n/a | n/a | -US$12m |
| Mar 31 2021 | n/a | n/a | -US$14m |
| Dec 31 2020 | US$2m | US$505k | -US$16m |
| Sep 30 2020 | n/a | n/a | -US$18m |
| Jun 30 2020 | n/a | n/a | -US$17m |
| Mar 31 2020 | n/a | n/a | -US$12m |
| Dec 31 2019 | US$472k | US$472k | -US$9m |
| Sep 30 2019 | n/a | n/a | -US$13m |
| Jun 30 2019 | n/a | n/a | -US$13m |
| Mar 31 2019 | n/a | n/a | -US$39m |
| Dec 31 2018 | US$653k | US$460k | -US$40m |
| Sep 30 2018 | n/a | n/a | -US$32m |
| Jun 30 2018 | n/a | n/a | -US$32m |
| Mar 31 2018 | n/a | n/a | -US$6m |
| Dec 31 2017 | US$1m | US$216k | -US$6m |
Compensation vs Market: Chris's total compensation ($USD520.00K) is about average for companies of similar size in the US market ($USD674.55K).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
CEO
Chris Xu (52 yo)
7.5yrs
Tenure
US$520,000
Compensation
Dr. Xiaochun Xu, also known as Chris, M.B.A. Ph D., serves as Chief Executive Officer and Chairman at ImmuneCyte Life Sciences, Inc. Dr. Xu is the Founder, Chairman and Chief Executive Officer of Boyalife...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 7.5yrs | US$520.00k | no data | |
| CFO & Corporate Secretary | 7.2yrs | US$264.00k | 0.00025% $ 13.8 | |
| Chief Operating Officer | 6.3yrs | US$460.00k | 0% $ 0 |
7.2yrs
Average Tenure
52yo
Average Age
Experienced Management: THMO's management team is seasoned and experienced (7.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 8.2yrs | US$520.00k | no data | |
| Independent Director | 7.3yrs | US$54.50k | 0% $ 0 | |
| Member of Clinical & Scientific Advisory Board | 10yrs | no data | no data | |
| Member of Clinical Advisory Board | 8.2yrs | no data | no data | |
| Independent Director | less than a year | US$13.38k | 0% $ 0 | |
| Independent Director | 7.3yrs | US$56.00k | 0% $ 0 | |
| Independent Director | less than a year | US$10.00k | no data |
7.3yrs
Average Tenure
57yo
Average Age
Experienced Board: THMO's board of directors are considered experienced (7.3 years average tenure).